• CloudMD has nominated Duncan Hannay and Karen Adams to the company’s board of directors
  • Duncan is the current CEO of OLG Corporation
  • Karen is the current president of CloudMD as well as its Global Head, Enterprise Health Solutions
  • Both candidates offer more than 20 years of experience creating growth in business
  • Mark Kohler (Chairman), Christopher Cherry (Independent) and Essam Hazma (CEO) are up for re-election to the board
  • CloudMD has appointed KPMG LLP, Chartered Professional Accountants as the company’s independent auditors
  • CloudMD is digitizing the delivery of healthcare by providing a patient-centric approach, with an emphasis on continuity of care.
  • CloudMD Software & Services Inc. (DOC) is down 3.11 per cent, trading at C$1.56 per share at 1:15 pm ET

CloudMD has nominated Duncan Hannay and Karen Adams to the company’s board of directors.

Duncan is the current CEO of OLG Corporation. Karen is the current president of CloudMD as well as its Global Head, Enterprise Health Solutions.

Both candidates offer more than 20 years of experience creating growth in business.

Dr. Essam Hazma, CEO of CloudMD said he is excited to have Hannay and Adams up for nomination.

“We are thrilled to welcome Duncan and Karen to our Board of Directors as their collective experience and leadership will be extremely valuable to the continued growth of our company… Each of these outstanding individuals brings valuable expertise and insight that will help position CloudMD for long-term success as an innovative healthcare company.”

Up for re-election for the board of directors are Mark Kohler (Chairman), Christopher Cherry (Independent) and Essam Hazma (CEO).

CloudMD also announces that it has appointed KPMG LLP, Chartered Professional Accountants as the company’s independent auditors to hold office until the end of the next annual general meeting of shareholders.

As of Sept. 9th, 2021, CloudMD’s predecessor auditors resigned, and KPMG has been appointed to fill their vacancy for the fiscal year ended on Dec. 31st, 2021.

CloudMD has granted stock options and RSU’s in course to certain directors and officers under its Stock Option Plan and RSU Plan to purchase 1,250,000 shares of the company. The price of the stock options granted was set at $1.75 per share.

CloudMD is transforming healthcare by using technology and works with hybrid primary care clinics, specialist care, telemedicine, mental health support, healthcare navigation, educational resources, and AI’s.

CloudMD Software & Services Inc. (DOC) is down 3.11 per cent, trading at C$1.56 per share at 1:15 pm ET.

More From The Market Online

Canadian biotech stock investigates potential weight loss drugs

FSD Pharma Inc. (CSE:HUGE) is expanding its pipeline into metabolic and related disorders including weight loss and liver health.
The Market Online Video

Emerging opportunity in a growing, high-value dermatological market

Kane Biotech (TSXV:KNE) engages in the development and commercialization of products that prevent and remove microbial biofilms.